2026 Q2 - tulosraportti
27 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 319 | - | - | ||
| 18 | - | - | ||
| 535 | - | - | ||
| 1 921 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenToday's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.
·13 t sittenFirst patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html- ·2 päivää sittenUnleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
·10.9.I must admit that I am a bit puzzled by this company. It has existed for almost 109 years, but how? Or is there a mistake in the year, so it should say 2017? There should probably be a bit more money in the till and a slightly higher stock price when one has been in the game for 109 years 🤔GulTomat Regarding the share price, I think it's the shareholders who determine the price. Now that Bioporto has become a commercial company, they need to go out and prove that they at least keep what they promise. So far, they are sticking to the plan that has been presented. The fact that Bioporto now has a target for how many hospitals they close deals with is a new way to measure whether Bioporto will reach its goals. But historically, it has been the case that in the first 3 quarters, closing deals was slow, because the board of directors at the American hospitals had set a budget for the entire year, and therefore it has always been in Q4 where Bioporto closed deals with the most hospitals. Now that KDIGO has published their recommendations in the spring, we have been able to see that Bioporto has closed deals with 6 hospitals in Q2, and this is because KDIGO published recommendations already in the spring. My expectations are: In short, that Bioporto will close at least 6 new deals in Q3, and when KDIGO finally finishes rewriting the documents, the rest will follow, affected by the two strongest recommendations. I expect many positive news in the next many quarters.- ·4.9.updated investment case BioPorto: Q2 met all parameters in the long-term plan The valuation of BioPorto has been updated with a base-case probability of success of 62%, focusing on delivery on the three pillars to close the upside gap. https://www.inderes.dk/research/bioporto-q2-levede-op-til-alle-parametre-i-den-langsigtet-plan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |
2026 Q2 - tulosraportti
27 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenToday's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.
- ·13 t sittenFirst patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html
- ·2 päivää sittenUnleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
- ·10.9.I must admit that I am a bit puzzled by this company. It has existed for almost 109 years, but how? Or is there a mistake in the year, so it should say 2017? There should probably be a bit more money in the till and a slightly higher stock price when one has been in the game for 109 years 🤔GulTomat Regarding the share price, I think it's the shareholders who determine the price. Now that Bioporto has become a commercial company, they need to go out and prove that they at least keep what they promise. So far, they are sticking to the plan that has been presented. The fact that Bioporto now has a target for how many hospitals they close deals with is a new way to measure whether Bioporto will reach its goals. But historically, it has been the case that in the first 3 quarters, closing deals was slow, because the board of directors at the American hospitals had set a budget for the entire year, and therefore it has always been in Q4 where Bioporto closed deals with the most hospitals. Now that KDIGO has published their recommendations in the spring, we have been able to see that Bioporto has closed deals with 6 hospitals in Q2, and this is because KDIGO published recommendations already in the spring. My expectations are: In short, that Bioporto will close at least 6 new deals in Q3, and when KDIGO finally finishes rewriting the documents, the rest will follow, affected by the two strongest recommendations. I expect many positive news in the next many quarters.
- ·4.9.updated investment case BioPorto: Q2 met all parameters in the long-term plan The valuation of BioPorto has been updated with a base-case probability of success of 62%, focusing on delivery on the three pillars to close the upside gap. https://www.inderes.dk/research/bioporto-q2-levede-op-til-alle-parametre-i-den-langsigtet-plan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 319 | - | - | ||
| 18 | - | - | ||
| 535 | - | - | ||
| 1 921 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |
2026 Q2 - tulosraportti
27 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenToday's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.
- ·13 t sittenFirst patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html
- ·2 päivää sittenUnleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
- ·10.9.I must admit that I am a bit puzzled by this company. It has existed for almost 109 years, but how? Or is there a mistake in the year, so it should say 2017? There should probably be a bit more money in the till and a slightly higher stock price when one has been in the game for 109 years 🤔GulTomat Regarding the share price, I think it's the shareholders who determine the price. Now that Bioporto has become a commercial company, they need to go out and prove that they at least keep what they promise. So far, they are sticking to the plan that has been presented. The fact that Bioporto now has a target for how many hospitals they close deals with is a new way to measure whether Bioporto will reach its goals. But historically, it has been the case that in the first 3 quarters, closing deals was slow, because the board of directors at the American hospitals had set a budget for the entire year, and therefore it has always been in Q4 where Bioporto closed deals with the most hospitals. Now that KDIGO has published their recommendations in the spring, we have been able to see that Bioporto has closed deals with 6 hospitals in Q2, and this is because KDIGO published recommendations already in the spring. My expectations are: In short, that Bioporto will close at least 6 new deals in Q3, and when KDIGO finally finishes rewriting the documents, the rest will follow, affected by the two strongest recommendations. I expect many positive news in the next many quarters.
- ·4.9.updated investment case BioPorto: Q2 met all parameters in the long-term plan The valuation of BioPorto has been updated with a base-case probability of success of 62%, focusing on delivery on the three pillars to close the upside gap. https://www.inderes.dk/research/bioporto-q2-levede-op-til-alle-parametre-i-den-langsigtet-plan
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 319 | - | - | ||
| 18 | - | - | ||
| 535 | - | - | ||
| 1 921 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 172 952 | 172 952 | 0 | 0 |